Skip to content

Study · Observational study · n = 17 · 2026

9 results

Real-World Outcomes of Vosoritide Treatment in Chinese Children with Achondroplasia: The Retrospective Cohort COREV Study.

Chen L, Zhang X, Zhang X, Lu W, Xiao Y, Wang F, Shang H, Yang Y, Xu Y, Yang Y, Gu Z, Ma X, Su W, Dong Z

Advances in therapy28 Jul 2026

PMID42518139 (opens in a new tab)DOI10.1007/s12325-026-03719-9 (opens in a new tab)PepBankPUB-42518139
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In vosoritide-treated Chinese children with achondroplasia, height SDS increased from -4.7 ± 0.1 to -4.3 ± 0.2 at 12 months (P < 0.001).

    In plain wordsIn Chinese children with achondroplasia, vosoritide treatment was linked to higher height scores at 12 months than baseline.

    Peptide
    Vosoritide
    Outcome
    IncreaseHeight SDS at twelve months
    Study

    n = 17

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Height SDS at baseline
    −4.7 SDS
    baseline; ± 0.1 as written
    Height SDS at 12 months
    −4.3 SDS
    12 months; ± 0.2 as written; P < 0.001

    Source sentences

    Summary
    Among the 17 patients assessed at 12 months, height SDS (based on general population growth charts) improved from - 4.7 ± 0.1 at baseline to - 4.3 ± 0.2 at 12 months (P < 0.001).
    2 context sentences
    Summary · context
    A total of 26 children diagnosed with ACH and treated with vosoritide were enrolled in the study.
    Summary · context
    Clinical indicators such as height, sitting height, and body mass index (BMI), as well as laboratory indicators including bone age and insulin-like growth factor level, were collected and analyzed before and after treatment.
  2. 02HumanObservational studyEfficacy outcome

    In vosoritide-treated Chinese children with achondroplasia, AGV increased significantly to 8.7 ± 1.4 cm/year after 18 months.

    In plain wordsIn Chinese children with achondroplasia, vosoritide treatment was linked to increased growth velocity compared with before treatment.

    Peptide
    Vosoritide
    Outcome
    IncreaseAnnual growth velocity at eighteen months
    Study

    n = 12

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Measurements

    Annual growth velocity after 18 months of treatment
    8.7 cm/year
    12 patients under follow-up; ± 1.4 as written

    Source sentences

    Summary
    With continued treatment, annual growth velocity (AGV) significantly increased, reaching 8.7 ± 1.4 cm/year in 12 patients who remained under follow-up after 18 months of treatment.
    2 context sentences
    Summary · context
    A total of 26 children diagnosed with ACH and treated with vosoritide were enrolled in the study.
    Summary · context
    Clinical indicators such as height, sitting height, and body mass index (BMI), as well as laboratory indicators including bone age and insulin-like growth factor level, were collected and analyzed before and after treatment.
  3. 03HumanObservational studyEfficacy outcome

    In vosoritide-treated Chinese children with achondroplasia, BMI SDS declined continuously during treatment.

    In plain wordsIn Chinese children with achondroplasia, vosoritide treatment was linked to declining BMI scores compared with before treatment.

    Peptide
    Vosoritide
    Outcome
    DecreaseBMI SDS
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, BMI SDS exhibited a continuous decline.
    2 context sentences
    Summary · context
    A total of 26 children diagnosed with ACH and treated with vosoritide were enrolled in the study.
    Summary · context
    Clinical indicators such as height, sitting height, and body mass index (BMI), as well as laboratory indicators including bone age and insulin-like growth factor level, were collected and analyzed before and after treatment.
  4. 04HumanObservational studyEfficacy outcome

    In vosoritide-treated Chinese children with achondroplasia, sitting height/height ratio decreased during treatment.

    In plain wordsIn Chinese children with achondroplasia, vosoritide treatment was linked to a lower sitting height/height ratio than before treatment.

    Peptide
    Vosoritide
    Outcome
    DecreaseSitting height/height ratio
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The sitting height/height ratio decreased during the treatment, indicating an optimization of body proportions.
    2 context sentences
    Summary · context
    A total of 26 children diagnosed with ACH and treated with vosoritide were enrolled in the study.
    Summary · context
    Clinical indicators such as height, sitting height, and body mass index (BMI), as well as laboratory indicators including bone age and insulin-like growth factor level, were collected and analyzed before and after treatment.
  5. 05HumanObservational studyEfficacy outcome

    In vosoritide-treated Chinese children with achondroplasia, growth improved in groups below and above five years and in male and female groups.

    In plain wordsIn Chinese children receiving vosoritide, growth improved in groups below and above five years and in male and female groups.

    Peptide
    Vosoritide
    Outcome
    IncreaseGrowth improvement across age and sex groups
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Additionally, growth improvement was found in both age (below five years old and above five years old) and sex (male and female) groups.
    2 context sentences
    Summary · context
    A total of 26 children diagnosed with ACH and treated with vosoritide were enrolled in the study.
    Summary · context
    Clinical indicators such as height, sitting height, and body mass index (BMI), as well as laboratory indicators including bone age and insulin-like growth factor level, were collected and analyzed before and after treatment.
  6. 06HumanObservational studyEfficacy outcome

    In vosoritide-treated Chinese children with achondroplasia, TP1NP increased significantly at 12 months versus baseline.

    In plain wordsIn Chinese children with achondroplasia, vosoritide treatment was linked to higher TP1NP at 12 months than baseline.

    Peptide
    Vosoritide
    Outcome
    IncreaseTP1NP at twelve months
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Except for the total procollagen I intact N-terminal (TP1NP), which significantly increased at 12 months of treatment compared to baseline, other biochemical indicators (including insulin-like growth factor, alkaline phosphatase, and osteocalcin) showed no significant differences after the treatment.
    2 context sentences
    Summary · context
    A total of 26 children diagnosed with ACH and treated with vosoritide were enrolled in the study.
    Summary · context
    Clinical indicators such as height, sitting height, and body mass index (BMI), as well as laboratory indicators including bone age and insulin-like growth factor level, were collected and analyzed before and after treatment.
  7. 07HumanObservational studyEfficacy outcome

    In vosoritide-treated Chinese children with achondroplasia, insulin-like growth factor showed no significant difference after treatment versus baseline.

    In plain wordsIn Chinese children with achondroplasia, insulin-like growth factor did not change significantly during vosoritide treatment versus baseline.

    Peptide
    Vosoritide
    Outcome
    No significant changeInsulin-like growth factor
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Except for the total procollagen I intact N-terminal (TP1NP), which significantly increased at 12 months of treatment compared to baseline, other biochemical indicators (including insulin-like growth factor, alkaline phosphatase, and osteocalcin) showed no significant differences after the treatment.
    2 context sentences
    Summary · context
    A total of 26 children diagnosed with ACH and treated with vosoritide were enrolled in the study.
    Summary · context
    Clinical indicators such as height, sitting height, and body mass index (BMI), as well as laboratory indicators including bone age and insulin-like growth factor level, were collected and analyzed before and after treatment.
  8. 08HumanObservational studyEfficacy outcome

    In vosoritide-treated Chinese children with achondroplasia, alkaline phosphatase showed no significant difference after treatment versus baseline.

    In plain wordsIn Chinese children with achondroplasia, alkaline phosphatase did not change significantly during vosoritide treatment versus baseline.

    Peptide
    Vosoritide
    Outcome
    No significant changeAlkaline phosphatase
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Except for the total procollagen I intact N-terminal (TP1NP), which significantly increased at 12 months of treatment compared to baseline, other biochemical indicators (including insulin-like growth factor, alkaline phosphatase, and osteocalcin) showed no significant differences after the treatment.
    2 context sentences
    Summary · context
    A total of 26 children diagnosed with ACH and treated with vosoritide were enrolled in the study.
    Summary · context
    Clinical indicators such as height, sitting height, and body mass index (BMI), as well as laboratory indicators including bone age and insulin-like growth factor level, were collected and analyzed before and after treatment.
  9. 09HumanObservational studyEfficacy outcome

    In vosoritide-treated Chinese children with achondroplasia, osteocalcin showed no significant difference after treatment versus baseline.

    In plain wordsIn Chinese children with achondroplasia, osteocalcin did not change significantly during vosoritide treatment versus baseline.

    Peptide
    Vosoritide
    Outcome
    No significant changeOsteocalcin
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Except for the total procollagen I intact N-terminal (TP1NP), which significantly increased at 12 months of treatment compared to baseline, other biochemical indicators (including insulin-like growth factor, alkaline phosphatase, and osteocalcin) showed no significant differences after the treatment.
    2 context sentences
    Summary · context
    A total of 26 children diagnosed with ACH and treated with vosoritide were enrolled in the study.
    Summary · context
    Clinical indicators such as height, sitting height, and body mass index (BMI), as well as laboratory indicators including bone age and insulin-like growth factor level, were collected and analyzed before and after treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.